Vaccine for traveler's diarrhea may be within reach
NEW YORK (Reuters Health) - A test vaccine against Campylobacter jejuni, a major cause of traveler's diarrhea, provided protection against infection in mice and monkeys and may ultimately have human application, according to researchers.
In addition to causing diarrhea, C. jejuni is also associated with a number of "important sequelae," including inflammatory bowel disease, senior investigator Dr. Patricia Guerry told Reuters Health. No licensed vaccines for C. jejuni are currently available.
As reported in the March issue of Infection and Immunity, Guerry of the Naval Medical Research Center, Silver Spring, Maryland and colleagues develop a vaccine for C. jejuni and tested it in mice and monkeys challenged with C. jejuni infection. Following vaccination mice demonstrated significant immune response and reduction in disease.
The vaccine also completely protected monkeys from diarrhea caused by C. jejuni.
"We are very excited about these results," said Guerry. She thinks that a vaccine that could protect against various types of C. jejuni is "very feasible."
Her team, Guerry added, has recently obtained funding from National Institute of Allergy and Infectious Diseases to continue their studies.
SOURCE: Infection and Immunity, March 2009.
- Six killed, including four children, in Houston-area shooting |
- Palestinian death toll rises to 74 as Israel hits Gaza over rocket fire |
- Anger mounts as Germany unearths second U.S. spy suspect
- Exclusive: Iraq tells U.N. that 'terrorist groups' seized nuclear materials
- Portugal woes sink European stocks